DGAP-Adhoc: SYGNIS AG receives commitment for the purchase

SYGNIS AG  / Key word(s): Capital Increase

29.06.2016 19:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement according to § 15 WpHG

---------------------------------------------------------------------------
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE USA, CANADA,
JAPAN AND AUSTRALIA


SYGNIS AG receives commitment for the purchase of up to 2.7 million shares
within the scope of a capital increase to finance the acquistion of
Expedeon Holdings Ltd.


Madrid, Spain and Heidelberg, Germany, 29 June 2016 - SYGNIS AG (Frankfurt:
LIO1; ISIN: DE000A1RFM03; Prime Standard) today received a binding
commitment for the purchase of up to 2.7 million new shares as part of the
previously announced cash capital increase to finance the acquisition of
Expedeon Holdings Ltd. Under the terms of the agreement signed today, the
investor has committed to purchase up to 2.7 million shares which are not
subscribed by SYGNIS or Expedeon shareholders in a private placement at a
price of EUR 1.10 per new share.

XXX end of ad hoc announcement XXX

For further information, please contact:


SYGNIS AG                         MC Services AG
Pilar de la Huerta                Raimund Gabriel
CEO/CFO                           Managing Partner
Phone: +34 91 192 36 50           Phone: +49 89 210228 30
Email: pdelahuerta@sygnis.com     Email: raimund.gabriel@mc-services.eu



About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes in the development
and commercialization of innovative products for DNA amplification and
sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast-growing
fields of molecular biology and next-generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to a leading industry partner, for whole genome DNA amplification
and sequencing, as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed on the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information
contained herein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in the Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind
of offer or solicitation is prohibited or lacks the required permission.
Potential investors in securities of SYGNIS AG are asked to familiarize
themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on
the basis of the securities prospectus detailing the public offering of
securities of SYGNIS AG in the Federal Republic of Germany, which, subject
to the approval of the German Federal Financial Supervisory Authority
(BaFin) is anticipated to be published under www.sygnis.com/investors.

The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to U.S.
Persons (as defined in regulation S of the U.S. Securities Act of 1933) or
to publications with a general circulation in the United States with the
exception of a such disclosures or announcements outside the Federal
Republic of Germany which have to be made under the respective mandatory
law. Any person who fails to comply with these restrictions may violate the
security laws of certain jurisdictions, in particular of the United States.
Securities in SYGNIS AG are not publicly offered outside the Federal
Republic of Germany.

Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of
future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are
subject to known and unknown risks and imponderability and can be affected
by other factors as a consequence of which the actual results, plans and
goals of SYGNIS AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not undertake
to publicly update or revise these statements in the light of new
information or future results or for any other reason.###


29.06.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      SYGNIS AG
              Waldhofer Str. 104
              69123 Heidelberg
              Germany
Phone:        +49 (0) 6221 3540 125
Fax:          +49 (0) 6221 3540 127
E-mail:        investors@sygnis.com
Internet:     www.sygnis.com
ISIN:         DE000A1RFM03
WKN:          A1RFM0
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
              Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
DGAP-Adhoc: SYGNIS AG receives commitment for the purchase of up to 2.7 million shares within the scope of a capital increase to finance the acquistion of Expedeon Holdings Ltd.
